Brief: Rigel Pharmaceuticals Q1 EPS USD 0.64 Vs. IBES Estimate USD 0.02
06/05/2025 21:01
May 06 (Reuters) - Rigel Pharmaceuticals Q1 net income USD 11.4 million vs. IBES estimate USD 1.66 million. Q1 revenue USD 53.3 million vs. IBES estimate USD 43.9 million
Recent news on Rigel Pharmaceuticals
See all newsU.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
Rigel Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rigel Pharmaceuticals Q2 revenue rises on strong product demand
Brief: Rigel Pharmaceuticals - Appoints Alison L. Hannah As Executive Vice President And Chief Medical Officer Effective July 1, 2026 - SEC Filing
Brief: Rigel Announces Closing Of Licensing Agreement For Veppanu (Vepdegestrant)